الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 236 |  |  |
| | | from | 236 | | |
Abstract
More than 50,000 hematopoietic stem cell transplantation (HSCT) procedures are done every year worldwide for a variety of malignant and benign diseases. (1) Severe aplastic anemia (SAA) is a life-threatening disease characterized by pancytopenia and a hypocellular bone marrow. (2) A young adult patient having SAA is best treated with HSCT using HLA matched sibling donor, but still the risk of graft versus host disease (GvHD) and its high morbidity and mortality rate continue to impact the choice between HSCT versus immunosuppressive therapy (IST) as an initial treatment in adults with SAA. (3) Post-transplantation cyclophosphamide (PTCY) has become widely used as GvHD prophylaxis (4), it has been used in matched related donor transplants and haploidentical transplants resulting in a lower incidence of acute and chronic GvHD. (5, 6) In attempt to evaluate the effect of post-transplant cyclophosphamide in adult Egyptian patients with severe aplastic anemia having HSCT from fully HLA-matched sibling donors and its effect on the outcome regarding acute and chronic GvHD and overall survival this work was designed.